Which is more effective, rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Analysis from the British Society for Rheumatology Biologics Register.

M Soliman; K Hyrich; M Lunt; K Watson; D Symmons; D. Ashcroft

Which is more effective, rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Analysis from the British Society for Rheumatology Biologics Register.

M Soliman, K Hyrich, M Lunt, K Watson, D Symmons, D. Ashcroft

Research output: Chapter in Book/Conference proceeding › Conference contribution

Original language	English
Title of host publication	Pharmacoepidemiology and Drug Safety; 20: S13
Publisher	John Wiley & Sons Ltd
Publication status	Published - 2011

Cite this

@inproceedings{4801637733da4595807caf043680a1d5,

title = "Which is more effective, rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Analysis from the British Society for Rheumatology Biologics Register.",

author = "M Soliman and K Hyrich and M Lunt and K Watson and D Symmons and D. Ashcroft",

year = "2011",

language = "English",

booktitle = "Pharmacoepidemiology and Drug Safety; 20: S13",

publisher = "John Wiley & Sons Ltd",

address = "United Kingdom",

}

Which is more effective, rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Analysis from the British Society for Rheumatology Biologics Register. / Soliman, M; Hyrich, K; Lunt, M et al.
Pharmacoepidemiology and Drug Safety; 20: S13. John Wiley & Sons Ltd, 2011.

Research output: Chapter in Book/Conference proceeding › Conference contribution

TY - GEN

T1 - Which is more effective, rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Analysis from the British Society for Rheumatology Biologics Register.

AU - Soliman, M

AU - Hyrich, K

AU - Lunt, M

AU - Watson, K

AU - Symmons, D

AU - Ashcroft, D.

PY - 2011

Y1 - 2011

M3 - Conference contribution

BT - Pharmacoepidemiology and Drug Safety; 20: S13

PB - John Wiley & Sons Ltd

ER -